Alnylam receives european commission approval for amvuttra® (vutrisiran) for the treatment of attr amyloidosis with cardiomyopathy

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rna interference (rnai) therapeutics company, today announced that the european commission (ec) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (attr-cm) as an additional indication for its orphan rnai therapeutic amvuttra® (vutrisiran). the approval broadens the indication for amvuttra, which now becomes the first and onl.
ALNY Ratings Summary
ALNY Quant Ranking